Retinitis Pigmentosa is a genetically inherited eye disorder that progressively damages the photoreceptor cells of the retina, beginning with night blindness and gradually narrowing the field of vision. Left unaddressed, it can advance toward significant, irreversible vision loss. India has emerged as a preferred destination for Stem cell therapy for Retinitis Pigmentosa in Pakistan, drawing patients who are searching for options beyond what conventional ophthalmology currently offers. That said, it remains important to note that achieving a definitive cure for this condition is still a complex and ongoing pursuit within the medical field.
Advances in stem cell research have opened new therapeutic avenues for patients living with inherited retinal disorders. In the case of **Stem cell therapy for Retinitis Pigmentosa, a condition marked by the progressive degeneration of rod and cone photoreceptor cells, this approach is viewed as a source of cautious optimism rather than a guaranteed remedy. Stem cell-based treatments work by supporting the regenerative environment of the retina — encouraging repair processes, supporting surviving photoreceptor cells, and, in some patients, contributing to the stabilization of further vision decline.
Mesenchymal stem cell injections administered via the Retro-bulbar route have become a widely used approach for RP patients, generally requiring one or two treatment sessions. This technique has shown an encouraging track record in supporting the regenerative capacity of retinal cells affected by inherited degeneration. The regenerative reach of these stem cells extends to multiple retinal cell types, including photoreceptor cells, retinal pigment epithelium cells, and optic nerve cells, giving this therapy broad relevance across the different stages of RP.
For patients from Pakistan seeking support beyond what is locally available, the Eye Stem Cell Center has been delivering specialized eye

